A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study
B. J. Monk, M. F. Brady, C. Aghajanian, H. A. Lankes, T. Rizack, J. Leach, J. M. Fowler, R. Higgins, P. Hanjani, M. Morgan, R. Edwards, W. Bradley, T. Kolevska, P. Foukas, E. M. Swisher, K. S. Anderson, R. Gottardo, J. K. Bryan, M. Newkirk, K. L. ManjarrezR. S. Mannel, R. M. Hershberg, G. Coukos
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study'. Together they form a unique fingerprint.